Glenn did his PhD at the University of Sydney before postdoctoral studies at the University of Oxford. After academic stints at the University of Sydney and the University of Connecticut Health Center, he joined the Institute for Molecular Bioscience in 2007. Glenn is a leader in the field of venoms-based drug and insecticide discovery. His early work on venoms led him to found Vestaron Corporation, an agricultural biotechnology company that has developed bee-safe, eco-friendly bioinsecticides. Glenn’s current research focuses on the development of therapeutics to treat cardiovascular and nervous system disorders. He recently co-founded Infensa Bioscience, a biotech company that is developing drugs for treating stroke and myocardial infarction, and he currently serves as the company’s Chief Scientific Officer. Glenn’s laboratory maintains one of the largest venom collections in the world, sourced from more than 500 species of venomous invertebrates. In 2023 Glenn received the Prime Minister’s Prize for Innovation for his translational work, and he was elected a Fellow of the Australian Academy of Science in 2024.